Skip to content
Beacon

BIOYGraniteshares YieldBOOST Biotech ETF

Get incomeNewRanked #1,606 of 1,639 in this goal

The Fund’s primary investment objective is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index by selling options on leveraged ETFs.

By Graniteshares · Launched 2026

Annual Cost

1.07%

#5,143 of 5,584 · expensive

Fund Size

$0.7M

#5,523 of 5,584 · small

Dividend YieldGoal

—

Track Record

1 month

#5,428 of 5,584 · young

Performance

Total-return NAV · USD
Growth of $10,000
$9,855-1.5%

Total-return NAV, USD. Net of fund fees, before tax.

What's inside

How Beacon categorizes this fund

Asset class

Alternative

Region

North america

Strategy

Option income

Index tracked

S&P Biotechnology Select Industry Index

What it actually holds

By weight

Asset allocation

Bonds
54.8%
Cash
45.3%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years
Volatility (1Y)
N/A
Max drawdown
-5.0%Mild

Worst peak-to-trough loss

Sharpe (3Y)
Unavailable

Needs 3+ years of history

Sortino (3Y)
Not yet

Needs 3+ years of history

Listing

Exchange
NASDAQ Global Select Market

Full fund details

Objective
The Fund’s primary investment objective is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index by selling options on leveraged ETFs.
Strategy
Actively managed ETF that seeks to pay weekly distributions by selling put options on the Underlying Leveraged ETF, which provides exposure to 3 times the daily performance of the Underlying Index.
Inception date
May 4, 2026
Fund family
Graniteshares

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Covered call
Warning

The big yield isn't extra money

The headline distribution comes from selling call options, which caps the fund's upside. Across a full market cycle that trade costs more than it brings in — often 1 to 3 percentage points a year against just holding the index. Monthly payouts make the gap easy to miss on a return summary.

Sources: Israelov & Ndong, 'A Devil's Bargain: When Generating Income Undermines Investment Returns' (NDVR, 2023)

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've looked at BIOY. Save it to your watchlist to weigh it against other funds, then turn your shortlist into a portfolio.

See other funds for this goal

Data updated on 2026-06-23